Table 5

Disease-specific outcome measures in autoimmune neuromuscular diseases

Condition	Established disability measure	MCID
Chronic inflammatory demyelinating polyneuropathy	MRC sum score*58	±2 points
	CIDP-RODS†59 60	±4 points (logit scale)
	Vigorimeter (kPa)‡61	±8 kPa
	10 m timed walk (s)62	±28% change
	ONLS60 63
Other neuropathy /neuromyotonia	INCAT†64	±1 point
	Berg balance scale†62	±8 points
	ABC balance score†65	<50%: low function
	Tremor scale†66
	Myotonia behaviour scale†67
Multifocal motor neuropathy	MRC sum score*58	±2 points
	Vigorimeter (kPa)‡61	±8 kPa
	MMN-RODS†68	±4 points (logit scale)
	ONLS60 63
Inflammatory myopathy	MRC sum score*58	±2 points
	Timed up and go 3 m walk (s)69
	CK	±30% change
	HAQ Score†57	±15% change
	Physician global activity assessment70	±20% change
	Patient/parent global activity assessment70	±20% change
	Manual muscle testing71	±15% change
	MDAAT72
Myasthenia gravis	MG composite†73
	MG-ADL Score74	±3 points
	Respiratory function, for example, forced vital capacity	±10% change

*At our centre, measurement of first dorsal interosseous is added to the standard six pairs of muscle groups, to better reflect the pattern of weakness in neuropathy.
†Validated.
‡Responsive.
ABC, activities-specific balance confidence; CIDP, chronic inflammatory demyelinating polyneuropathy; CK, creatine kinase; HAQ, health assessment questionnaire; INCAT, inflammatory neuropathy cause and treatment; MCID, minimal clinical indication of change; MDAAT, myositis disease activity assessment tool; MG, myasthenia gravis; MG-ADL, myasthenia gravis activities of daily living; MMN, multifocal motor neuropathy; MRC, Medical Research Council; ONLS, overall neuropathy limitations scale; RODS, rasch-built overall disability scale.